Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose steroid plus long-acting beta2-agonist vs higher-dose steroid in allergic asthma
2007-000097-23Phase 4Terminated
- Sponsor
- GSK
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of salmeterol + fluticasone and fluticasone propionate in allergic asthma and asthma (3 arms), sponsored by GSK. Primary endpoint: Mean change in neutrophil priming in blood as assessed by marker A17. Started Aug 2007; status: terminated.
02
Drugs
salmeterol + fluticasonefluticasone propionate
03
Conditions
allergic asthmaasthma
Beyond the preview
Go deeper on 2007-000097-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000097-23.